Kit for carrying out BRCA1 / 2 gene sequence detection on pre-implantation embryo and application thereof
Through transcriptome-based kits, reverse transcription and specific nucleic acid sequence amplification technology, the difficulty and error of BRCA1/2 gene detection before embryo implantation is solved, and high-precision embryo gene detection is achieved, suitable for difficult detection. Embryos, improve success rate.
Patent Information
- Application Number
- CN202411129340.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-12
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-16
AI Technical Summary
The existing BRCA1/2 gene mutation detection has difficulty and errors before embryo implantation, especially due to the small amount of genomic DNA and the dispersion of mutation sites, the possibility of detection vulnerabilities and errors is high, and it depends on family linkage analysis. , it is difficult to conduct accurate detection of embryos directly.
Provide a transcriptome-based kit that performs preimplantation embryo detection of BRCA1 and BRCA2 genes through reverse transcription and specific nucleic acid sequence amplification, and uses specific primer pairs to perform PCR amplification and sequencing analysis to reduce the risk of tripping. Directly detect the embryo's mutation sites and avoid relying on family chain analysis.
It improves the detection accuracy of the BRCA1/2 gene in embryonic cells, reduces detection failure and error, and can directly conduct accurate detection of embryos. It is suitable for embryos that are difficult to detect, and improves the success rate.
Smart Images

Figure CN118910262A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Chinese invention patent application No. 202311166861.2 filed on September 12, 2023, which is incorporated herein by reference. Technical Field
[0003] The present invention relates to the field of biomedicine, and in particular to a kit for detecting BRCA1 / 2 gene sequences in pre-implantation embryos and uses thereof. Background Art
[0004] Breast cancer is one of the most common malignant tumors in women in most countries. Currently, its incidence rate in developing countries accounts for 23% of all types of tumors. The World Health Organization report shows that the incidence rate of breast cancer is increasing at a rate of 2% year by year. A related survey in 2015 showed that there are about 260,000 new breast cancer patients each year, causing about 70,000 deaths each year. Studies have found that 10-15% of breast cancers are caused by genetic gene mutations. In the 1990s, BRCA1 and BRCA2 (breast cancer susceptibility gene) were confirmed as the pathogenic genes of hereditary breast and ovarian cancer (HBOC).
[0005] BRCA1, located on chromosome 17, consists of 22 exons and encodes 1863 amino acids of the 220kD breast cancer susceptibility protein BRCA1. BRCA1 is mainly involved in cell cycle regulation, DNA damage repair, gene transcription activation, tumor growth inhibition and other cellular activities. BRCA2, located on chromosome 13, has a gene larger than BRCA1. It has a 10.3kB open reading frame, consists of 27 exons, and encodes a BRCA2 protein composed of 3418 amino acids. This protein has also been shown to play an important role in DNA damage repair.
[0006] The probability of a normal woman suffering from breast cancer in her lifetime is about 13%, and the probability of suffering from ovarian cancer is about
[0007] 1.2%, but in contrast, women who inherit harmful BRCA1 / 2 mutations have a 55%–72% chance of developing breast cancer and a 39%–44% chance of developing ovarian cancer. In addition, harmful mutations in BRCA1 and BRCA2 increase the risk of several other cancers, such as fallopian tube cancer and primary peritoneal cancer. For men, men who carry harmful mutations in the BRCA1 / 2 genes also have an increased risk of developing breast cancer and prostate cancer. Breast cancer and ovarian cancer are highly malignant, with expensive surgery and a long follow-up treatment period, which brings a large economic burden and mental loss to both society and individuals, and is also a great challenge to human health.
[0008] The American Society of Clinical Oncology's current recommendations for BRCA1 / 2-related HBOC are that all women diagnosed with epithelial ovarian cancer or women with multiple family members who have breast cancer should undergo genetic testing for genetic variations in BRCA1, BRCA2, and other tumor susceptibility genes. Second-generation sequencing and Sanger sequencing can confirm the type of mutation that occurs in most patients, but so far this method can only be used to test surviving family members in the family in order to take preventive surgery, and cannot fundamentally address the impact of BRCA1 / 2 gene mutations on offspring.
[0009] Preimplantation genetic testing for monogenic defects (PGT-M) can effectively block the transmission of harmful mutations in the BRCA1 / 2 gene to offspring. By selecting embryo genotypes, embryos that do not carry harmful mutations can be screened, and families with the disease can have healthy offspring, reducing the impact of BRCA1 / 2 gene mutations on society and families. Currently, PGT-M mainly obtains trace genetic analysis materials through biopsy at the blastocyst stage, and then conducts subsequent diagnostic analysis after whole-genome amplification (WGA). Compared with traditional prenatal genetic diagnosis (PND), PGT-M tests preimplantation embryos to avoid physical and mental harm to women caused by induced labor of fetuses carrying mutations.
[0010] However, adult genetic testing uses peripheral blood samples, from which microgram-level genomic DNA can be extracted, and Sanger sequencing or second-generation sequencing technology is subsequently used to detect mutation sites. The samples for preimplantation embryo genetic testing come from cells (about 5 cells) biopsied from the extraembryo trophectoderm (TE) of the blastocyst stage. The amount of genomic DNA is at the picogram level, which is far different from the genomic DNA obtained from peripheral blood of adults.
[0011] Since the BRCA1 / 2 gene sequences are long and the mutation forms are diverse, the mutation sites are scattered throughout the entire length of the two genes. The current WGA coverage is about 80-85%. Direct site detection after WGA has a risk of allele drop-out (ADO) of up to 20%. In addition, not all BRCA1 / 2 gene mutations will damage protein function. For patients with new germline mutations, family linkage analysis based on single nucleotide polymorphisms (SNPs) or short tandem repeats (STRs) cannot accurately diagnose the embryo. Therefore, in the current conventional detection methods, there are detection loopholes and the possibility of detection errors. Summary of the invention
[0012] In order to solve the aforementioned problems, the present invention provides a transcriptome-based kit for detecting BRCA1 and / or BRCA2 gene sequences in pre-implantation embryos and its application.
[0013] In a first aspect, the present invention provides a kit for detecting the BRCA1 gene sequence of preimplantation embryos, characterized in that the kit comprises at least one of the following primer pairs:
[0014] Primer pair 1
[0015] Covering BRCA1 gene exon 1-8, amplified fragment length 903bp
[0016] First upstream primer: CCTCTGCTCTGGGTAAAGT (SEQ ID No: 1)
[0017] The first downstream primer: CTGCTGTTCTCATGCTGTAATG (SEQ ID No: 2);
[0018] Primer pair 2
[0019] Covering exon 9 of BRCA1 gene, the amplified fragment length is 3706bp
[0020] The second upstream primer: CAGTGTGGGAGATCAAGAATTG (SEQ ID No: 3) The second downstream primer: GATGGAAGGGTAGCTGTTAGA (SEQ ID No: 4);
[0021] Primer pair 3
[0022] Covering BRCA1 gene exon 10-22, amplified fragment length 1704bp
[0023] The third upstream primer: GTTGGTCTGAGTGACAAGGAA (SEQ ID No: 5)
[0024] The third downstream primer: AGGACAGTAGAAGGACTGAAGA (SEQ ID No: 6).
[0025] In a second aspect, the present invention provides a kit for detecting the BRCA2 gene sequence of preimplantation embryos, characterized in that the kit comprises at least one of the following primer pairs:
[0026] Primer pair 4
[0027] Covering BRCA2 gene exons 1-9, amplified fragment length 2461bp
[0028] Upstream primer: AAAGAACTGCACCTCTGGA (SEQ ID No: 7)
[0029] Downstream primer: CCTTTGAGCTTGTCTGACATTT (SEQ ID No: 8);
[0030] Primer pair 5
[0031] Covering exon 10 of BRCA2 gene, the amplified fragment length is 5397bp
[0032] Upstream primer: CCTCTGAAAGTGGACTGGAAATA (SEQ ID No: 9)
[0033] Downstream primer: GTACACAGGTAATCGGCTCTAAA (SEQ ID No: 10);
[0034] Primer pair 6
[0035] Covering BRCA2 gene exon 11-27, amplified fragment length 3665bp
[0036] Upstream primer: AGTCATGCCACACATTCTCTT (SEQ ID No: 11)
[0037] Downstream primer: CGATACACAAACGCTGAGGTA (SEQ ID No: 12).
[0038] In a third aspect, the present invention provides a kit for detecting BRCA1 and / or BRCA2 gene sequences in pre-implantation embryos, characterized in that it comprises the kit described in the first aspect and the kit described in the second aspect.
[0039] In a fourth aspect, the present invention provides a system for detecting BRCA1 and / or BRCA2 gene sequences in preimplantation embryos, comprising:
[0040] A sample pre-processing device, the sample pre-processing device is used to obtain a nucleic acid sample from an outer trophoblast cell;
[0041] a specific nucleic acid sequence amplification device, the specific nucleic acid sequence amplification device being connected to the sample pretreatment device and used to amplify the target gene using the kit set according to claim 3;
[0042] A sequencing device is connected to the specific nucleic acid sequence amplification device so as to perform sequencing analysis on the amplified product.
[0043] Furthermore, in some embodiments, the sample preprocessing device comprises:
[0044] A cell lysis unit, wherein the outer trophoblast cells are fully lysed to expose the mRNA therein;
[0045] A reverse transcription unit, which is obtained by adding a reverse transcription reagent to the cell lysis unit and is used to perform a reverse transcription reaction on the mRNA to obtain cDNA;
[0046] A nucleic acid amplification unit is used in the nucleic acid amplification unit to amplify the cDNA using fixed sequence upstream and downstream primers to obtain the nucleic acid sample.
[0047] Optionally, the exotrophoblast cells are exotrophoblast cells at the blastocyst stage.
[0048] Optionally, lysing cells in the cell lysis unit is performed as follows:
[0049] The outer trophoblast cells are placed in a lysis solution, fully shaken for 30-60 seconds, and then incubated at 72° C. to fully lyse the cells. The lysis solution contains RNase inhibitor, dNTP, Triton X-100, and nuclease-free water.
[0050] Optionally, the sample pretreatment device further comprises a purification unit, and before obtaining the nucleic acid sample, the product obtained by the nucleic acid amplification unit is purified using magnetic beads in the purification unit.
[0051] Optionally, the preparation of cDNA template is carried out as follows: the lysed exotrophoblast cells are added to a reverse transcription system to synthesize a complementary cDNA chain, wherein the reverse transcription system includes an RNase inhibitor, dNTP, a polyT primer, Triton X-100, SuperScript II reverse transcriptase, 0.1M DTT, betaine Betaine (5M), MgCl2 (1M), Superscript II first chain buffer (5×), nuclease-free water, and a fixed end sequence; further preferably, the reverse transcription program is: 25°C for 5 minutes; 42°C for 60 minutes; 50°C for 30 minutes; 70°C for 10 minutes; and hold at 4°C.
[0052] Optionally, the PCR amplification of the cDNA template is carried out as follows: an amplification mixture is added to the cDNA template, the amplification mixture comprising Taq DNA synthetase, a fixed sequence upstream primer, a fixed sequence downstream primer, and nuclease-free water; further preferably, the amplification program is: 95°C for 3 minutes; 14 to 18 cycles: 98°C for 20 seconds, 66°C for 15 seconds, 72°C for 5 minutes; 72°C for 5 minutes; and maintained at 4°C.
[0053] Optionally, the purification of the amplified cDNA template is performed by purifying the product obtained after amplification using 0.8× magnetic beads (Beckman) to remove primer sequences and small fragment sequences below 200 bp in the reverse transcription and amplification processes.
[0054] Optionally, the PCR system is as follows: 20 μL of PCR amplification reagent (including dNTP, DNA polymerase, magnesium ions, etc.) are mixed evenly; 1 μL of upstream and downstream primers each; 2 μL of cDNA template, 17 μL of ddH2O; a further preferred PCR program is: 94°C for 5 minutes; 35-38 cycles: 94°C for 30 seconds, 57°C for 30 seconds, 72°C for 4 minutes; 72°C for 10 minutes; keep at 4°C.
[0055] In a fifth aspect, the present invention provides a method for detecting BRCA1 / 2 gene sequences in pre-implantation embryos based on gene expression in extraembryonic trophoblastic cells, which method is not used for disease diagnosis and treatment, and comprises the following steps:
[0056] S1: reverse transcription of extraembryonic trophoblast mRNA to obtain cDNA;
[0057] S2: amplifying and purifying the cDNA to obtain a nucleic acid sample;
[0058] S3: amplifying the nucleic acid sample using the kit according to claim 1 or 2;
[0059] S4: The amplified product of S3 was subjected to Sanger sequencing and aligned with the reference genome sequence.
[0060] Furthermore, in step S4, the sequencing result is compared with the reference genome. If they are consistent, the pathogenic variant is not carried; if the site is heterozygous and the pathogenic variant allele is observed, the pathogenic variant is carried.
[0061] In a seventh aspect, the present invention provides the use of the kit described in the first to second aspects for detecting the BRCA1 / 2 gene sequence in pre-implantation embryos.
[0062] The advantages of the present invention include at least the following:
[0063] 1. Detection of genomic BRCA1 / 2 at the single-cell level of the embryo is difficult because there are only two copies. After whole-genome amplification, detection is difficult and there is a risk of detection failure and miss detection. The applicant found through analysis that BRCA1 / 2 genes are highly expressed in the extra-trophoblast cells of the blastocyst in the early stage of embryonic development. The number of mRNA copies produced by cell transcription is significantly higher than the two copies of the genome. During the reverse transcription and amplification process of the transcriptome, the possibility of miss detection is reduced, thereby improving the accuracy of BRCA1 / 2 gene detection in pre-implantation embryonic cells.
[0064] 2. A kit for detecting the BRCA1 / 2 gene sequence in pre-implantation embryos is provided. It does not require peripheral blood samples from core family members of both the male and female to construct chromosome haplotype information, and does not rely on family linkage analysis for double detection. It can directly detect the variant sites of the embryo, which reduces the difficulty of amplification and has a high detection success rate. It provides a new method for embryo detection families with difficult linkage analysis.
[0065] 3. Universal primer design can detect all mutations within the gene. It has a wide detection range and good universality, and does not need to be designed for each individual. BRIEF DESCRIPTION OF THE DRAWINGS
[0066] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings:
[0067] Figure 1 .Agarose gel electrophoresis of BRCA1 primer PCR products;
[0068] Figure 2 .Agarose gel electrophoresis of BRCA2 primer PCR products;
[0069] Figure 3. Sanger sequencing results of the PCR product amplified by primer 1, covering BRCA1 exons 1-8, the amplified fragment length is 903bp, the starting region of exon 1 of the BRCA1 gene, and the red dotted box indicates the ATG start codon;
[0070] Figure 4 . Sanger sequencing results of the PCR product amplified by primer 1, covering BRCA1 exons 1-8, with a 903 bp amplified fragment. The red dotted box shows the end region of exon 8 of the BRCA1 gene, and the right side shows the start region of exon 9;
[0071] Figure 5 . Sanger sequencing results of the PCR product amplified by primer 2 (covering BRCA1 exon 9, amplified fragment length 3706bp), the red dotted box shows the start region of exon 9 of the BRCA1 gene, and the left side is the end region of exon 8;
[0072] Figure 6 . Sanger sequencing results of the PCR product amplified by primer 2 (covering BRCA1 exon 9, amplified fragment length 3706bp), the red dotted box shows the end region of exon 9 of the BRCA1 gene, and the right side is the start region of exon 10;
[0073] Figure 7 . Sanger sequencing results of the PCR product amplified by primer 3 (covering BRCA1 exon 10-22, amplified fragment length 1704bp), the red dotted box shows the start region of exon 10 of the BRCA1 gene, and the left side is the end region of exon 9;
[0074] Figure 8 . Sanger sequencing results of the PCR product amplified by primer 3 (covering BRCA1 exon 10-22, amplified fragment length 1704bp), the red dotted box shows the terminal region of exon 22 of the BRCA1 gene (including the TGA stop codon);
[0075] Fig. 9 . Sanger sequencing results of the PCR product amplified by primer 4 (covering BRCA2 exons 1-9, amplified fragment length 2461bp), the red dotted box shows the start region of exon 1 of the BRCA2 gene (including the ATG start codon);
[0076] Fig.10 . Sanger sequencing results of the PCR product amplified by primer 4 (covering BRCA2 exons 1-9, amplified fragment length 2461bp), the red dotted box shows the end region of exon 9 of the BRCA2 gene, and the right side is the start region of exon 10;
[0077] Fig.11 . Sanger sequencing results of the PCR product amplified by primer 5 (covering BRCA2 exon 10, amplified fragment length 5397bp), the red dotted box shows the start region of exon 10 of the BRCA2 gene, and the left side is the end region of exon 9;
[0078] Fig.12 . Sanger sequencing results of the PCR product amplified by primer 5 (covering BRCA2 exon 10, amplified fragment length 5397bp), the red dotted box shows the end region of exon 10 of the BRCA2 gene, and the right side is the start region of exon 11;
[0079] Fig.13 . Sanger sequencing results of the PCR product amplified by primer 6 (covering BRCA2 exons 11-27, amplified fragment length 3665bp), the red dotted box shows the start region of exon 11 of the BRCA2 gene, and the left side is the end region of exon 10;
[0080] Fig.14 . Sanger sequencing results of the PCR product amplified by primer 6 (covering BRCA2 exons 11-27, amplified fragment length 3665bp), the red dotted box shows the terminal region of exon 27 of the BRCA2 gene (including the TAA stop codon);
[0081] Fig.15 . Example 1 family E1 Sanger sequencing peak diagram;
[0082] Fig.16 . Example 1 family E2 Sanger sequencing peak diagram;
[0083] Fig.17 . Example 1 family E3 Sanger sequencing peak diagram;
[0084] Fig.18 . Example 2 Family E1 Sanger sequencing peak diagram;
[0085] Fig.19 Example 2: Sanger sequencing peak diagram of family E2. DETAILED DESCRIPTION
[0086] The preferred embodiments of the present invention are described below in conjunction with the accompanying drawings. It should be understood that the preferred embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0087] Example 1
[0088] A kit for BRCA1 gene sequence detection in preimplantation embryos, the kit contains the following primer pairs:
[0089] Primer pair 1
[0090] Covering BRCA1 gene exon 1-8, amplified fragment length 903bp
[0091] First upstream primer: CCTCTGCTCTGGGTAAAGT (SEQ ID No: 1)
[0092] The first downstream primer: CTGCTGTTCTCATGCTGTAATG (SEQ ID No: 2);
[0093] Primer pair 2
[0094] Covering exon 9 of BRCA1 gene, the amplified fragment length is 3706bp
[0095] The second upstream primer: CAGTGTGGGAGATCAAGAATTG (SEQ ID No: 3) The second downstream primer: GATGGAAGGGTAGCTGTTAGA (SEQ ID No: 4);
[0096] Primer pair 3
[0097] Covering BRCA1 gene exon 10-22, amplified fragment length 1704bp
[0098] The third upstream primer: GTTGGTCTGAGTGACAAGGAA (SEQ ID No: 5) The third downstream primer: AGGACAGTAGAAGGACTGAAGA (SEQ ID No: 6).
[0099] PCR and sequencing were performed using three primer pairs for the BRCA1 gene and human cell cDNA. The results are shown in Figure 1 and Figure 3-8 , indicating that the primers are available and the sequence is correct.
[0100] Example 2
[0101] A kit for detecting the BRCA12 gene sequence in preimplantation embryos, comprising the following primer pairs: Primer pair 4
[0102] Covering BRCA2 gene exons 1-9, amplified fragment length 2461bp
[0103] Upstream primer: AAAGAACTGCACCTCTGGA (SEQ ID No: 7)
[0104] Downstream primer: CCTTTGAGCTTGTCTGACATTT (SEQ ID No: 8);
[0105] Primer pair 5
[0106] Covering exon 10 of BRCA2 gene, the amplified fragment length is 5397bp
[0107] Upstream primer: CCTCTGAAAGTGGACTGGAAATA (SEQ ID No: 9)
[0108] Downstream primer: GTACACAGGTAATCGGCTCTAAA (SEQ ID No: 10);
[0109] Primer pair 6
[0110] Covering BRCA2 gene exon 11-27, amplified fragment length 3665bp
[0111] Upstream primer: AGTCATGCCACACATTCTCTT (SEQ ID No: 11)
[0112] Downstream primer: CGATACACAAACGCTGAGGTA (SEQ ID No: 12).
[0113] PCR and sequencing were performed using three primer pairs of the BRCA2 gene and human cell cDNA, respectively. The results are shown in Figure 2 and Figure 9-14 , indicating that the primers are available and the sequence is correct.
[0114] Example 3
[0115] A kit for detecting BRCA1 / 2 gene sequences in pre-implantation embryos, comprising the kits of embodiments 1 to 2, and may further comprise reagents one to four as described below.
[0116] Reagent 1 (cell sample lysis buffer): Triton X-100, RNase inhibitor, nuclease-free water, dNTP
[0117] Reagent 2 (reverse transcription mixture): SuperScript II reverse transcriptase, Superscript II first-strand synthesis buffer (5×), random primers or terminal fixed sequence (100μM), polyT primer, RNase inhibitor, DTT (0.1M), Betaine (5M), dNTP, MgCl2 (1M), nuclease-free water
[0118] Reagent 3 (cDNA amplification mixture): random primers or fixed sequence upstream primers, random primers or fixed sequence downstream primers, Taq DNA polymerase, nuclease-free water
[0119] Reagent 4 (target fragment amplification mixture): dNTP, nuclease-free water, high-fidelity DNA polymerase, Mg2+, etc.
[0120] Steps for using the kit:
[0121] S1: reverse transcription of the mRNA of the extraembryonic trophoblast cells to obtain cDNA amplification and purification of the product;
[0122] S2: amplify and purify most cDNAs to obtain nucleic acid samples;
[0123] S3: amplifying the nucleic acid sample using at least one of the kits in Examples 1 and 2;
[0124] S4: The amplified product of S3 was subjected to Sanger sequencing and aligned with the reference genome sequence.
[0125] Furthermore, in step S4, the sequencing result is compared with the reference genome. If they are consistent, the pathogenic variant is not carried; if the site is heterozygous and the pathogenic variant allele is observed, the pathogenic variant is carried.
[0126] Further,
[0127] Step S1 specifically includes the following steps:
[0128] S1-1: Obtaining embryo cell samples and storage: The fertilized eggs are obtained by intracytoplasmic sperm injection, cultured to the blastocyst stage, and the blastocysts are biopsied for the outer trophoblast cells, and about 3 cells are obtained for each sample. The obtained cell samples are collected in reagent 1 and can be stored in a -80℃ refrigerator for a short period of time;
[0129] S1-2: Cell lysis: Shake thoroughly for 30-60 seconds and incubate at 72°C for 3 minutes to fully lyse the cell sample;
[0130] S1-3: Reverse transcription: Add reagent 2 to the lysed sample to reverse transcribe the transcriptome mRNA into cDNA. The reverse transcription program is: 25℃ for 5 minutes, 42℃ for 60 minutes, 50℃ for 30 minutes, 70℃ for 10 minutes, and maintain at 4℃;
[0131] Step S2 specifically includes the following steps:
[0132] S2-1: Amplify cDNA: Add reagent 3 to the cDNA product obtained in S1-3 for PCR amplification. The specific reaction procedure is: 95℃ for 3min; 18 cycles: 98℃ for 20s, 66℃ for 15s, 72℃ for 5min; 72℃ for 5min; store at 4℃;
[0133] S2-2: Purification of cDNA products: Use 0.8×Agencourt AMPure XP Beads magnetic beads to purify the amplified cDNA products, remove the primer sequences in the reverse transcription and amplification process, and small fragment sequences below 200 bp, to obtain samples with higher purity.
[0134] S3: Use the purified cDNA product obtained in S2 as a template and use the primer pair to amplify the target region. The PCR amplification system is: 18 μL of reagent four, 1-2 μL of cDNA template, 0.5 μL of each upstream and downstream primer (10 μmol / L) of each primer pair. The PCR amplification reaction program is: 94°C for 5 minutes; 35 cycles: 94°C for 30 seconds, 57°C for 30 seconds, 72°C for 4 minutes; 72°C for 10 minutes; 4°C hold.
[0135] S4: The PCR target product obtained in S3 was subjected to Sanger sequencing (Sangong / Tianyi Huiyuan) and compared with the reference sequence.
[0136] Embodiment 4:
[0137] In an in vitro experiment, the method described in Example 3 was carried out using the kit of Example 1:
[0138] The male's mother in this family is a breast cancer patient. Genetic testing at an external hospital showed that the male and his mother carried the BRCA1 gene c.2572C>T heterozygous mutation. Both husband and wife underwent BRCA1 gene genetic blockade through PGT-M.
[0139] 1. Acquisition of blastocyst extracellular trophoblast cell samples
[0140] After intracytoplasmic sperm injection, a total of 3 fertilized eggs developed into blastocysts (embryo 1, embryo 2, and embryo 3). The 3 embryos were biopsied for extrablastocyst trophoblast cells, and 3 extrablastocyst trophoblast cells were obtained from embryo 1, 3 extrablastocyst trophoblast cells were obtained from embryo 2, and 4 extrablastocyst trophoblast cells were obtained from embryo 3. The collected cell samples of embryo 1, embryo 2, and embryo 3 were placed in lysis buffer (the components of the lysis buffer were RNase inhibitor, dNTP, Triton X-100, and nuclease-free water, and the lysis buffer was a self-prepared reagent), and the collected samples were stored at -80°C.
[0141] 2. Obtain enough cDNA for detection
[0142] 2.1 Cell lysis
[0143] The cell samples of embryo 1, embryo 2, and embryo 3 were shaken thoroughly for 30-60 seconds and then incubated at 72°C for 3 minutes to allow the cells to fully lyse.
[0144] 2.2 Synthesis of complementary cDNA strands
[0145] Add the reverse mixed solution to the embryo 1, embryo 2, and embryo 3 samples after lysis in 2.1 to synthesize the complementary cDNA chain. The reverse system is a self-made reagent, and the components include RNase inhibitor, dNTP, polyT primer, Triton X-100, Superscript II reverse transcriptase, 0.1M DTT, betaine Betaine (5M), MgCl2 (1M) Superscript II first chain buffer (5×), nuclease-free water, and end fixed sequence. The reverse program is: 25℃ 5min; 42℃ 60min; 50℃ 30min; 70℃ 10min; 4℃ storage.
[0146] 2.3 PCR amplification to obtain cDNA
[0147] Add amplification mixture to the embryo 1, embryo 2, and embryo 3 samples obtained in 2.2, including TagDNA synthetase, fixed sequence upstream primer, fixed sequence downstream primer, and nuclease-free water. The amplification program is: 95℃ 3min; 18 cycles: 98℃ 20s, 66℃ 15s, 72℃ 5min; 72℃ 5min; 4℃ storage.
[0148] 2.4 cDNA purification
[0149] The products of embryo 1, embryo 2, and embryo 3 obtained after amplification were purified using 0.8× magnetic beads (Beckman) to remove primer sequences in the reverse transcription and amplification process, as well as small fragment sequences below 200 bp, to obtain cNDA samples.
[0150] 3. BRCA1 / 2 gene c.DNA targeted amplification
[0151] The family mutation c.2572C>T is located in exon 9. The primer pairs were used to perform PCR amplification on the cDNA samples of embryo 1, embryo 2, and embryo 3. The PCR system was as follows: 20 μL of PCR amplification reagent (including dNTP, DNA polymerase, magnesium ions, etc.) was mixed evenly; 1 μL of upstream and downstream primers; 2 μL of cDNA template of embryo 1 / embryo 2 / embryo 3 obtained in 2.4, and 17 μL of ddH2O. The PCR program was: 94°C 5 min; 35 cycles: 94°C 30 s, 58°C 30 s, 72°C 4 min; 72°C 10 min; 4°C storage. The product was sent to a first-generation sequencing company for Sanger sequencing (Sangong / Tianyi Huiyuan).
[0152] 4. Sanger sequencing analysis of pathogenic variants
[0153] Chromas software was used to analyze the sequencing results to check whether the BRCA1 gene c.2572C>T mutation was present. Figure 1 As shown in the figure, embryo 1 has a double peak at this site. Compared with the reference genome, one of the allele chains has a point mutation at position 2572, changing from C to T. Therefore, the diagnosis result is that embryo 1 carries this mutation. Figure 2 As shown, the position of embryo 2 is G, and there is no mutation in the preceding and following sequences, which is consistent with the reference genome, that is, embryo 2 does not carry the gene mutation. Figure 3 As shown, the site in embryo 3 is G, and there is no mutation in the preceding and following sequences, which is consistent with the reference genome, that is, embryo 2 does not carry the gene mutation.
[0154] Embodiment 4:
[0155] In an in vitro experiment, the method described in Example 3 was carried out using the kit of Example 2:
[0156] The female in this family was found to have a heterozygous mutation of c.4415_4418del in the BRCA2 gene during a physical examination. The female's aunt was a breast cancer patient and carried the heterozygous mutation, but the female's mother did not carry the mutation. Genetic testing later confirmed that the female's mutation was inherited from her father. The couple underwent BRCA2 gene genetic blockade through PGT-M.
[0157] 1. Acquisition of blastocyst extracellular trophoblast cell samples
[0158] After intracytoplasmic sperm injection, a total of 2 fertilized eggs developed into blastocysts (embryo 1 and embryo 2). The blastocyst extratrophoblast cells were biopsied for these 2 embryos, and 3 blastocyst extratrophoblast cells were obtained for embryo 1 and 3 blastocyst extratrophoblast cells were obtained for embryo 2. The collected cell samples of embryo 1 and embryo 2 were placed in lysis buffer (the lysis buffer contained RNase inhibitor, dNTP, Triton X-100, and nuclease-free water, and the lysis buffer was a self-prepared reagent), and the collected samples were stored at -80°C.
[0159] 2. Obtain enough cDNA for detection
[0160] 2.1 Cell lysis
[0161] The embryo 1 and embryo 2 cell samples were shaken thoroughly for 30-60 seconds and then incubated at 72°C for 3 minutes to allow the cells to fully lyse.
[0162] 2.2 Synthesis of complementary cDNA strands
[0163] Add the reverse mixed solution to the embryo 1 and embryo 2 samples after lysis in 2.1 to synthesize the complementary cDNA chain. The reverse system is a self-made reagent, and the components include RNase inhibitor, dNTP, polyT primer, Triton X-100, Superscript II reverse transcriptase, 0.1M DTT, betaine Betaine (5M), MgCl2 (1M) Superscript II first chain buffer (5×), nuclease-free water, and end fixed sequence. The reverse program is: 25℃ 5min; 42℃ 60min; 50℃ 30min; 70℃ 10min; 4℃ storage.
[0164] 2.3 PCR amplification to obtain cDNA
[0165] Add amplification mixture to the embryo 1 and embryo 2 samples obtained in 2.2, including Tag DNA synthase, fixed sequence upstream primer, fixed sequence downstream primer, and nuclease-free water. The amplification program is: 95℃ 3min; 18 cycles: 98℃ 20s, 66℃ 15s, 72℃ for 5min; 72℃ 5min; 4℃ storage.
[0166] 2.4 cDNA purification
[0167] The embryo 1 product and embryo 2 product obtained after amplification were purified using 0.8× magnetic beads (Beckman) to remove primer sequences in the reverse transcription and amplification process, as well as small fragment sequences below 200 bp, to obtain cNDA samples.
[0168] 3. BRCA1 / 2 gene c.DNA targeted amplification
[0169] The family mutation c.4415_4418del is located in exon 10. PCR amplification was performed on 5 pairs of embryo 1 and embryo 2 cDNA samples using primers. The PCR system is as follows: 20 μL of PCR amplification reagent (including dNTP, DNA polymerase, magnesium ions, etc.) was mixed evenly; 1 μL of upstream and downstream primers; 2 μL of cDNA template of embryo 1 / embryo 2 obtained in 2.4, 17 μL of ddH2O. The PCR program is: 94℃ 5min; 35 cycles: 94℃ 30s, 58℃ 30s, 72℃ 4min; 72℃ 10min; 4℃ storage. The product was sent to a first-generation sequencing company for Sanger sequencing (Sangong / Tianyi Huiyuan).
[0170] 4. Sanger sequencing analysis of pathogenic variants
[0171] Chromas software was used to analyze the sequencing results to check whether the BRCA2 gene c.4415_4418del mutation was present. Figure 4 As shown in the figure, the position of embryo 1 is AGAA, and there is no mutation in the sequence before and after, which is consistent with the reference genome. Therefore, the diagnosis result is that embryo 1 does not carry this mutation. Figure 5 As shown, the AGAA sequence at this position of embryo 2 is missing, and then the right sequence CAAA covers the original position, and then the sequence appears double peaks. Compared with the reference genome, one of the allele chains has a 4-base deletion at the position indicated by the horizontal line, that is, embryo 2 carries the BRCA2 gene c.4415_4418del mutation.
Claims
1. A kit for detecting the BRCA1 gene sequence of preimplantation embryos, characterized in that: The kit comprises at least one of the following primer pairs: Primer pair 1 First upstream primer: CCTCTGCTCTGGGTAAAGT (SEQ ID No: 1) The first downstream primer: CTGCTGTTCTCATGCTGTAATG (SEQ ID No: 2); Primer pair 2 The second upstream primer: CAGTGTGGGAGATCAAGAATTG (SEQ ID No: 3) The second downstream primer: GATGGAAGGGTAGCTGTTAGA (SEQ ID No: 4); Primer pair 3 The third upstream primer: GTTGGTCTGAGTGACAAGGAA (SEQ ID No: 5) The third downstream primer: AGGACAGTAGAAGGACTGAAGA (SEQ ID No: 6).
2. A kit for detecting the BRCA2 gene sequence of preimplantation embryos, characterized in that: The kit comprises at least one of the following primer pairs: Primer pair 4 Upstream primer: AAAGAACTGCACCTCTGGA (SEQ ID No: 7) Downstream primer: CCTTTGAGCTTGTCTGACATTT (SEQ ID No: 8); Primer pair 5 Upstream primer: CCTCTGAAAGTGGACTGGAAATA (SEQ ID No: 9) Downstream primer: GTACACAGGTAATCGGCTCTAAA (SEQ ID No: 10); Primer pair 6 Upstream primer: AGTCATGCCACACATTCTCTT (SEQ ID No: 11) Downstream primer: CGATACACAAACGCTGAGGTA (SEQ ID No: 12).
3. A kit for detecting BRCA1 and / or BRCA2 gene sequences in preimplantation embryos, characterized in that: The invention comprises the kit described in claims 1 and 2.
4. A system for detecting BRCA1 and / or BRCA2 gene sequences in preimplantation embryos, characterized in that: include: A sample pre-processing device, the sample pre-processing device is used to obtain a nucleic acid sample from an outer trophoblast cell; a specific nucleic acid sequence amplification device, the specific nucleic acid sequence amplification device being connected to the sample pretreatment device and used to amplify the target gene using the kit set according to claim 3; A sequencing device is connected to the specific nucleic acid sequence amplification device so as to perform sequencing analysis on the amplified product.
5. The system according to claim 4, characterized in that The sample preprocessing device comprises: A cell lysis unit, wherein the outer trophoblast cells are fully lysed to expose the mRNA therein; A reverse transcription unit, which is obtained by adding a reverse transcription reagent to the cell lysis unit and is used to perform a reverse transcription reaction on the mRNA to obtain cDNA; A nucleic acid amplification unit is used to amplify the cDNA to obtain the nucleic acid sample.
6. The system according to claim 5, characterized in that The exotrophoblast cells are exotrophoblast cells of the blastocyst stage.
7. A method for detecting the mRNA sequence of BRCA1 and / or BRCA2 genes in preimplantation embryos based on the gene expression of extraembryonic trophoblast cells, characterized in that: The following steps are involved: S1: reverse transcription of extraembryonic trophoblast mRNA to obtain cDNA; S2: amplifying and purifying the cDNA to obtain a nucleic acid sample; S3: amplifying the nucleic acid sample using the kit according to claim 1 or 2; S4: The amplified product of S3 was subjected to Sanger sequencing and aligned with the reference genome sequence.
8. The application method according to claim 7, characterized in that: In step S4, the sequencing result is compared with the reference genome. If they are consistent, the pathogenic variant is not carried; if the site is heterozygous and the pathogenic variant allele is observed, the pathogenic variant is carried.
9. Use of the kit described in claim 1 or 2 for detecting BRCA1 / 2 gene sequences in pre-implantation embryos.
Citation Information
Patent Citations
Nucleic acid detection kit for detecting BRCA1mRNA
CN102676663A
Method and primer for detecting mutation sites of all exon sequences of human BRCA1 and BRCA2 genes
CN104531862A
Method for identifying medical condition of human subject
CN116075598A
EXT1 or EXT2 diagnostic kit based on single cell transcriptome mRNA level
CN116287280A
Kit for carrying out Lingchi syndrome related gene sequence detection on pre-implantation embryo and application of kit
CN116640853A
